Last month, Santaris Pharma A/S announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders utilizing Santaris Pharma's proprietary LNA Drug Platform. This collaboration adds to the growing list of mRNA and microRNA drug discovery and development partnerships, which includes Wyeth (delivery of lead candidates against up to ten targets), GlaxoSmithKline (four viral disease drug candidates) and Enzon Pharmaceuticals (eight cancer targets successfully delivered). Operations in the US aim to support existing relationships and generate new licensing and partnership opportunities.
About Locked Nucleic Acid (LNA) Drug Platform
The Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetic chemical versions of the normal nucleic acid building blocks of ribonucleic acids (RNA). These synthetic chemical versions called LNAs improve the drug-like qualities of resulting therapeutics (oligonucleotides) by boosting resistance to metabolism, increasing half-life and improving tissue uptake. LNA-based therapeutics demonstrate improved binding affinity to their target RNA, which increases potency many-fold over other nucleotide therapeutics. The greater potency of LNA in binding complementary RNA sequences also allows for the use of significantly shorter LNA oligonucleotide drugs which can be more effective than previous antisense or siRNA drugs.
About Santaris Pharma A/S
Santaris Pharma A/S is a privately-held biopharmaceutical company focused
on developing RNA-based drugs targeted to disease-related mRNAs and
|SOURCE Santaris Pharma A/S|
Copyright©2009 PR Newswire.
All rights reserved